BACKGROUND: In rodents, CsA has been shown to affect T-cell development, giving rise to an abnormal production of mature T cells and the absence of many T-cell subsets as well as to autoimmunity. Surprisingly, only a few studies investigated the effect of the immunosuppressive drug on the immune system of the human fetus. METHODS: We examined six infants born to female kidney transplant recipients who had received cyclosporine and methylprednisolone throughout their pregnancies. Peripheral blood was obtained 1 day and 2, 4, 6, and 12 months after birth, and two-color flow cytometric immunophenotyping of lymphocytes was performed. RESULTS: Total T cells, as well as CD4+ and CD8+ T cells, were low at birth, but normalized thereafter. Among T-cell activation markers, the expression of CD25, the alpha chain of the interleukin-2 receptor, was below the normal range or low range throughout the study period, and HLA-DR expression was extremely low at birth and failed to increase up to 12 months. The number of total B cells was lower than normal at birth, but steeply increased over time. In contrast, B-cell subset bearing CD5 antigen was severely depleted throughout the first year of life. Total IgG concentration was significantly lower than in controls at 2 months, mainly because of subnormal levels of IgG1 and IgG3 subclasses, which remained in the low range up to 6 months. Finally, infants showed normal numbers of true natural killer (NK) cells (CD3-CD16+CD56+), whereas the expression of CD57 antigen, defining non-MHC-restricted cytotoxic lymphocytes, was barely detectable at birth and failed to increase over time, in both CD8+ and CD8- subsets. Of note, none of the infants had clinical evidence of an immunodeficient state. CONCLUSIONS: continuous exposure to CsA in utero seemingly impairs T-, B-, and NK-cell development and/or maturation, and most of its effects are still apparent at 1 year, which might suggest that conventional vaccinations should be delayed in these infants.
BACKGROUND: In rodents, CsA has been shown to affect T-cell development, giving rise to an abnormal production of mature T cells and the absence of many T-cell subsets as well as to autoimmunity. Surprisingly, only a few studies investigated the effect of the immunosuppressive drug on the immune system of the human fetus. METHODS: We examined six infants born to female kidney transplant recipients who had received cyclosporine and methylprednisolone throughout their pregnancies. Peripheral blood was obtained 1 day and 2, 4, 6, and 12 months after birth, and two-color flow cytometric immunophenotyping of lymphocytes was performed. RESULTS: Total T cells, as well as CD4+ and CD8+ T cells, were low at birth, but normalized thereafter. Among T-cell activation markers, the expression of CD25, the alpha chain of the interleukin-2 receptor, was below the normal range or low range throughout the study period, and HLA-DR expression was extremely low at birth and failed to increase up to 12 months. The number of total B cells was lower than normal at birth, but steeply increased over time. In contrast, B-cell subset bearing CD5 antigen was severely depleted throughout the first year of life. Total IgG concentration was significantly lower than in controls at 2 months, mainly because of subnormal levels of IgG1 and IgG3 subclasses, which remained in the low range up to 6 months. Finally, infants showed normal numbers of true natural killer (NK) cells (CD3-CD16+CD56+), whereas the expression of CD57 antigen, defining non-MHC-restricted cytotoxic lymphocytes, was barely detectable at birth and failed to increase over time, in both CD8+ and CD8- subsets. Of note, none of the infants had clinical evidence of an immunodeficient state. CONCLUSIONS: continuous exposure to CsA in utero seemingly impairs T-, B-, and NK-cell development and/or maturation, and most of its effects are still apparent at 1 year, which might suggest that conventional vaccinations should be delayed in these infants.
Authors: Cameron J McKinzie; Jillian P Casale; Jack C Guerci; Alyson Prom; Christina T Doligalski Journal: Paediatr Drugs Date: 2022-07-23 Impact factor: 3.930
Authors: M Isabel S Dinelli; Erika Ono; Patrícia O Viana; Amélia M N Dos Santos; M Isabel de Moraes-Pinto Journal: Eur J Pediatr Date: 2017-07-18 Impact factor: 3.183
Authors: Karolina Paziana; Magaly Del Monaco; Elyce Cardonick; Michael Moritz; Matthew Keller; Bruce Smith; Lisa Coscia; Vincent Armenti Journal: Drug Saf Date: 2013-05 Impact factor: 5.606
Authors: Srdjan Saso; Karl Logan; Yazan Abdallah; Louay S Louis; Sadaf Ghaem-Maghami; J Richard Smith; Giuseppe Del Priore Journal: J Transplant Date: 2011-11-10
Authors: Monika Østensen; Munther Khamashta; Michael Lockshin; Ann Parke; Antonio Brucato; Howard Carp; Andrea Doria; Raj Rai; Pierluigi Meroni; Irene Cetin; Ronald Derksen; Ware Branch; Mario Motta; Caroline Gordon; Guillermo Ruiz-Irastorza; Arsenio Spinillo; Deborah Friedman; Rolando Cimaz; Andrew Czeizel; Jean Charles Piette; Ricard Cervera; Roger A Levy; Maurizio Clementi; Sara De Carolis; Michelle Petri; Yehuda Shoenfeld; David Faden; Guido Valesini; Angela Tincani Journal: Arthritis Res Ther Date: 2006-05-11 Impact factor: 5.156